Earnings call Dr. Lal PathLabs delivered 10.6% YoY revenue growth in Q3 FY26, with EBITDA before exceptionals up 16.3% and margins stable at 27.2%. Management reiterated 11-12% organic growth focus, ...
Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated July 24, 2026, titled "Press Release on Un-audited Financial Results (Standalone ... Dr. Lal Path Labs Ltd. has ...
Dr. Lal PathLabs Limited has announced that its step-down subsidiary, Centrapath Labs Private Limited (CPL), has become a ...
Diagnostic healthcare provider Dr. Lal PathLabs Limited announced the acquisition of a 70 percent equity stake in SN Genelab ...
This article first appeared on GuruFocus. Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) is set to release its Q1 2027 earnings on Jul 24, 2026. The consensus estimate for Q1 2027 revenue is $7.60 billion, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results